Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies
Therapeutic treatment of bleeds with FVIII can lead to an antibody response that effectively inhibits its function. Herein, we review the factors that contribute to this immunogenicity and possible ways to overcome it.
Main Authors: | David W. Scott, Kathleen P. Pratt |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.03078/full |
Similar Items
-
A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
by: Alex C. Chen, et al.
Published: (2020-04-01) -
Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
by: Alexandra Sherman, et al.
Published: (2017-11-01) -
Tolerating Factor VIII: Recent Progress
by: Sebastien Lacroix-Desmazes, et al.
Published: (2020-01-01) -
Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies
by: Sébastien Lacroix-Desmazes, et al.
Published: (2021-01-01) -
Acquired factor VIII inhibitor syndrome: A rare cause of hematuria
by: Muthuvel Seral Kannan, et al.
Published: (2015-01-01)